Macrogenics Inc (MGNX) Stock Price & Analysis
Macrogenics Inc (MGNX) fell 7.73% to USD 3.7 as of July 25, 2026 at 03:44 UTC, according to Nexqual real-time market data.
MGNX last closed at USD 4.01; the session ranged USD 3.36–4.05 on volume of 2,653,511 shares. Market capitalization is $235.18M, with a 52-week range of USD 1.29–5.08 (NMS). Source: Nexqual, July 25, 2026 at 03:44 UTC.
Key Statistics (as of July 25, 2026 at 03:44 UTC)
| Price | USD 3.7 |
|---|---|
| Change | ▼ 7.73% (down) |
| Previous Close | USD 4.01 |
| Open | USD 4.01 |
| Day Range | USD 3.36 – 4.05 |
| 52-Week Range | USD 1.29 – 5.08 |
| Volume | 2,653,511 shares |
| Market Cap | $235.18M |
| Exchange | NMS |
Technical Analysis (MGNX)
Nexqual's technical model rates MGNX "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:44 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.39 (neutral) |
| vs SMA50 | Below (USD 4.31) |
| MACD | -0.06 (negative) |
Analyst Ratings (MGNX)
Wall Street analysts rate MGNX "Buy" based on 4 analysts, with a mean price target of USD 6.75 (range USD 4–9), per Nexqual as of July 25, 2026 at 03:44 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 6.75 |
| High Target | USD 9 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 3 / 4 / 0 |
Earnings (MGNX)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD 0.26 |
| Revenue Estimate | $59.14M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.58 vs est -0.55 ▼ miss |
| 2025-12-31 | USD -0.22 vs est -0.02 ▼ miss |
| 2025-09-30 | USD 0.27 vs est -0.51 ▲ beat |
| 2025-06-30 | USD -0.57 vs est 0.38 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:44 UTC.
Financials & Fundamentals (MGNX)
| Total Revenue | $157.08M |
|---|---|
| Revenue Growth (YoY) | +57.50% |
| Gross Margin | -16.24% |
| Operating Margin | -160.96% |
| Profit Margin | -44.79% |
| ROE | -140.27% |
| Debt / Equity | 172.23 |
| Current Ratio | 1.9 |
| Total Cash | $154.23M |
| Total Debt | $36.51M |
| Free Cash Flow | $10.11M |
Source: Nexqual, July 25, 2026 at 03:44 UTC.
Financial Health Score (MGNX)
Nexqual rates Macrogenics Inc's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:44 UTC.
| Growth | Weak — Revenue -0% YoY (annual), declining |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $154M cash vs $37M debt, net cash position |
| Cash Flow | Solid — FCF $10M, 7% margin |
| Efficiency | Critical — ROE -140%, ROA -18.0% |
Ownership (MGNX)
| Insider Ownership | +3.43% |
|---|---|
| Institutional Ownership | +69.05% |
| Shares Outstanding | 63.56M |
| Float | 55.88M |
| Short % of Float | +10.81% |
Source: Nexqual, July 25, 2026 at 03:44 UTC.
Leadership (MGNX)
Macrogenics Inc is led by Eric Blasius Risser (age 52), CEO, President & Director, per Nexqual as of July 25, 2026 at 03:44 UTC.
| CEO, President & Director | Eric Blasius Risser (age 52) |
|---|---|
| Senior VP & CFO | James Karrels (age 58) |
| Senior VP of Research & Chief Scientific Officer | Ezio Bonvini (age 71) |
| Senior Vice President of Technical Operations | Thomas M. Spitznagel (age 58) |
| Senior Vice President of Human Resources | Steve Harig |
Major Backers & Investors (MGNX)
Notable institutional backers of Macrogenics Inc include Armistice Capital, LLC, Renaissance Technologies, Millennium Management, according to Nexqual as of July 25, 2026 at 03:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 9.46% |
| Renaissance Technologies | 4.66% |
| Millennium Management | 4.4% |
| Acadian Asset Management. LLC | 4% |
| Two Sigma Investments, LP | 3.98% |
| Bank of America Corporation | 3.78% |
| Marshall Wace LLP | 3.19% |
| Wasatch Advisors LP | 3.18% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 10.14% |
Source: Nexqual, July 25, 2026 at 03:44 UTC.
From Macrogenics Inc's Latest SEC 10-K Filing (filed 2026-03-09)
Key Strengths & Strategy (as disclosed to the SEC)
- MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.
- The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| XNCR | Xencor, Inc. | USD 19.44 | ▼ 0.36% |
| KPTI | Karyopharm Therapeutics Inc. | USD 7.41 | ▲ 3.2% |
| CTMX | CytomX Therapeutics, Inc. | USD 3.24 | ▼ 2.7% |
| ATRA | Atara Biotherapeutics, Inc. | USD 7.9 | ▼ 2.77% |
| KYNB | Kyntra Bio, Inc. | USD 7.03 | ▼ 2.56% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:44 UTC. This page is informational and not investment advice.